Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTP-543 in moderate to severe alopecia areata
NCT03898479Phase 3Active, not recruiting
- Start
- Apr 2019
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of deuruxolitinib in alopecia areata. Primary endpoints: Adverse Events at 332 weeks and Severity of Alopecia Tool at 332 weeks. Started Apr 2019; status: active, not recruiting.
02
Drugs
deuruxolitinib
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT03898479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03898479.